Parkinson's Disease/Movement Disorders News

DENVER — A phase 3 trial of ulixacaltamide for essential tremor will involve at-home patient participation and a clinical endpoint of activities of daily living, according to a speaker at the American Academy of Neurology annual meeting.

On April 11, which marks World Parkinson’s Night, the patient-led organization PD Avengers will launch Spark the Night, a global initiative dedicated to raising awareness for Parkinson’s disease.

To mark this April as Parkinson’s Awareness Month, the Parkinson’s Foundation has created the #ABCsofPD to provide information about relevant symptoms, statistics and treatments.

A Swiss-based medical technology company has announced a partnership with Biogen to advance a digital biomarker platform involved in a planned clinical trial for BIIB122, a novel therapeutic to treat Parkinson’s disease.

A United Kingdom-based clinical-stage biotech company has announced commencement of a first-in-human clinical trial of a selective central nervous system-penetrant compound to treat Parkinson’s disease.

Compared with oral administration, continuous subcutaneous infusion of carbidopa/levodopa was linked to nearly 2 more hours of “on” time without dyskinesia in adults with Parkinson’s disease, data from The Lancet Neurology show.

CuraSen Therapeutics has announced positive data from a phase 2a study of its combination adrenergic activator, CST-2032/CST-107, for patients with mild cognitive impairment or mild dementia from Alzheimer’s or Parkinson’s disease.

A New York-based biopharmaceutical company has received a grant from Cure Parkinson’s to initiate a phase 2 clinical trial investigating dapansutrile, an oral small molecule, as a disease-modifying therapy for Parkinson’s disease.

Kathryn P. L. Moore, MD, MSc, assistant professor of neurology at Duke University School of Medicine, discusses therapies in the pipeline that are working to target the cause of Huntington's disease.

Kathryn P. L. Moore, MD, MSc, assistant professor of neurology at Duke University School of Medicine, discusses valbenazine, a recent approval in Huntington's disease care.